Related Experiment Video
Updated: Jul 4, 2025
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
12.5K
Central Nervous System Metastases in Pediatric Patients With Ewing Sarcoma
Leonora R Slatnick1, Carrye Cost2, Timothy Garrington2
1Department of Pediatrics, University of Utah, Division of Hematology/Oncology, Primary Children's Hospital, Salt Lake City, UT.
Journal of Pediatric Hematology/Oncology
|February 5, 2024
Summary
Metastatic central nervous system (CNS) involvement is rare in pediatric extracranial Ewing sarcoma (ES). This study found a poor prognosis for the 6 patients with CNS lesions, with short survival times after diagnosis.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Sarcoma Research
Background:
- Metastatic central nervous system (CNS) involvement is an uncommon complication of pediatric primary extracranial Ewing sarcoma (ES).
- Understanding the incidence and clinical course of CNS metastases in this population is crucial for treatment planning.
Purpose of the Study:
- To describe the incidence and clinical course of CNS metastatic lesions in pediatric patients with primary extracranial Ewing sarcoma.
- To evaluate survival outcomes following the detection of CNS disease in this rare patient cohort.
Main Methods:
- Retrospective case series analysis of 6 pediatric patients with extracranial ES and CNS metastases treated at a single institution.
- Analysis of time to CNS disease detection, event-free survival, and overall survival after CNS disease diagnosis.
Main Results:
- The median time to CNS disease detection was 16.3 months from initial diagnosis.
- Median event-free survival after CNS disease detection was 1.9 months, and median overall survival was 4.6 months.
- Only one patient remained alive at the time of analysis, indicating a grave prognosis.
Conclusions:
- Pediatric patients with extracranial Ewing sarcoma who develop CNS metastases have a very poor prognosis.
- Treatment decisions for aggressive interventions should carefully consider the patient's clinical status and the potential for disease control given the dismal survival rates.
